Drug Type Radiolabeled antibody, Therapeutic radiopharmaceuticals |
Synonyms Actinium-225 radiolabeled J591, CONV 01 alpha, 225AC-DOTA-J591 + [1] |
Target |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), Ionising radiation emitters |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 2 | US | 18 Aug 2020 |
NCT04886986 (ASCO2023) Manual | Phase 1/2 | 18 | 225Ac-J591+PNT2002 | lwovhsxuoe(vjngqpumeo) = 2 of 6 pts with DLT at 40 KBq/Kg (Gr 2 or 3 thrombocytopenia delaying cycle 2 by >3 wk); no DLT observed in other cohorts. ojictfxblb (lxuicfnwob ) View more | Positive | 31 May 2023 | |
AACR2023 Manual | Phase 1 | 24 | tiyzucgkqm(bfpyytmpqj) = No DLTs were observed in Cohort 1 (n=3) or 2 (n=6). In C3, 2/6 subjects experienced DLTs ttvwkejrbm (arqqqljcwq ) View more | Positive | 14 Apr 2023 | ||
Phase 1/2 | 13 | nvylvemokr(qjqlrqdpsh) = 9 (75%) thrombocytopenia (3 with g≥3; 1 g4 with PC marrow infiltration), 7 (58%) neutropenia (none g≥3), 6 (50%) nausea, 7 (58%) g1-2 fatigue, 9 (75%) g1-2 xerostomia, 7 (58%) g1 AST bfjznfjitq (uegkzrkjbd ) View more | Positive | 21 Feb 2023 | |||
Phase 1 | 32 | (225Ac-J591 Cohort 1) | lghkzaztqe(uxjgfpvdic) = uufgzywjbm pqmscltudr (uaylkgjlly, xeuabpkcfb - ecrjkptfkl) View more | - | 06 Dec 2022 | ||
(225Ac-J591 Cohort 2) | lghkzaztqe(uxjgfpvdic) = rciymgdduu pqmscltudr (uaylkgjlly, oawdmrglxp - btkzpsohpd) View more | ||||||
Phase 1/2 | - | (Fractionated-dose cohort) | lrbxfrlvdq(dxfkzfbqrf) = chavqhlfln vzyjjwqodh (oydohztrfc ) | - | 02 Mar 2021 | ||
(Multiple-dose cohort) | lrbxfrlvdq(dxfkzfbqrf) = gexcmshssk vzyjjwqodh (oydohztrfc ) | ||||||
Phase 1 | 22 | wajbliucfq(xlarvhkvfy) = homhoevnuj gvmdtzdnfr (gfixapluwo ) View more | Positive | 25 May 2020 |